摘要
Abstract
Objective:To explore the clinical efficacy of argatroban sequential therapy combined with alteplase thrombolysis in treating acute ischemic stroke(AIS).Methods:A total of 80 AIS patients admitted to a hospital from September 2022 to December 2024 were retrospectively selected and divided into the control group and the observation group according to different treatment regimens,with 40 patients in each group.Both groups were treated with edaravone injection.The control group was given alteplase for injection thrombolysis,while the observation group additionally received argatroban injection sequential therapy.The coagulation function indexes[thrombin time(TT),activated partial thromboplastin time(APTT),prothrombin time(PT)],hemorrhagic transformation(HT),inflammatory factors[C-reactive protein(CRP),tumor necrosis factor-α(TNF-α)],nerve injury factors[S100β protein,neuron-specific enolase(NSE)],clinical efficacy and adverse reactions were compared between the two groups.Results:After treatment,APTT,TT and PT were increased in both groups(P<0.05),with higher levels in the observation group(P<0.05).Levels of S100β protein,CRP,NSE and TNF-α were decreased in both groups(P<0.05),with lower levels in the observation group(P<0.05).The total clinical effective rate in the observation group(92.50%)was higher than that in the control group(75.00%,P<0.05).No statistically significant difference in the total incidence of adverse reaction and the incidence of HT was observed between the two groups(P>0.05).Conclusion:Argatroban sequential therapy combined with alteplase thrombolysis shows good clinical efficacy in AIS patients,effectively improving coagulation function,inhibiting inflammatory responses,relieving nerve damage,and does not increase the risk of adverse reactions.关键词
阿加曲班序贯疗法/阿替普酶/急性缺血性脑卒中/出血性转化/疗效Key words
argatroban sequential therapy/alteplase/acute ischemic stroke/hemorrhagic transformation/curative effect分类
医药卫生
